The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US. In 2009, Congress created a regulatory pathway for ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on comparative ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback